2007 AATOD Exhibitor Prospectus (PDF)

The National Conference serves as a central gathering point for the opioid treatment community and offers significant opportunities for exhibiting companies and attendees to interact with other professionals who are devoted to the treatment of opioid dependence throughout the nation and abroad. The registrants will consist of the decision makers in this field who spend over $1 billion annually treating more than 240,000 patients in opioid treatment programs.

In order to provide exhibitors with steady exposure to conference attendees, all continental breakfasts, refreshment breaks and poster sessions will be held exclusively in the exhibit area. An Exhibitor’s Reception will be held Monday, October 22nd to encourage contact and dialogue between opioid treatment professionals and the exhibiting companies.

Exhibit Kit
Cliick here

Exhibit Hours
Sunday, October 21 - 2:00 PM – 5:00 PM
Monday, October 22 - 7:30 AM – 3:30 PM and 5:00 pm – 6:30 pm
Tuesday, October 23 - 7:30 AM – 1:30 PM

List of Current Exhibitors
A. Company for SAAS Express

ACTION Campaign

Addiction Treatment Providers Insurance Program

American Association for the Treatment of Opioid Dependence, Inc. (AATOD)

Ammon Analytical Laboratory

ASIMV/Inflexxion, Inc.

Bendiner & Schlesinger, Inc.

Branan Medical Corporation

C & C Containers

California Organization of Opioid Maintenance Providers (COMP)

California Department of Alcohol and Drug Programs (ADP)

CARF

Cebert Pharmaceuticals

Clinical Science Laboratory, Inc.

Comstock Computing, LLC.

CRC Health Group

Darts, LLC

Drug Policy Alliance

eAnytime Kiosks, Inc.

Emerging Solutions in Pain/Medical Learning Solution

Friends Medical Laboratory, Inc.

International Diagnostic Systems

Kols Containers/OBNE

Covidien (formerly Mallinckrodt Pharmaceuticals)

Medication Assisted Therapies

National Institute on Drug Abuse (NIDA)

Netalytics

Netsmart Technologies, Inc.

Noble Medical, Inc.

NOVX Systems, Inc.

OraSure Technologies, Inc.

Price Consulting, Inc.

Reckitt Benckiser

Redwood Toxicology Laboratory, Inc.

Roche

RTI International

San Diego Reference Laboratory

Serene Center

Smart Management

Sterling Reference Laboratories

Substance Abuse and Mental Health Services Administration

Texas Opioid Treatment Alliance, Inc.

The Joint Commission

Tower Systems, Inc.

Treatment Software Solutions

Vendome Group, LLC

VistaPharm

Browse Table
Brown Consulting, Inc.
Vendome Group

 

Poster Sessions
Posters are in place at all times - Authors will present their topic on Tuesday from 7:30 AM - 8:45 AM

  • Methadone Maintenance and Lactation -
    Concentrations in Plasma and Breast Milk and
    Neonatal Neurobehavior
  • Increases in Methadone-Related Adverse Events- Is it
    Pills or Liquid?
  • An Evaluation of State Priorities - Guidelines and
    Funding for Infectious Disease Services in Substance
    Abuse Treatment Programs
  • Suboxone Induction Sites--A Model for Enhancing
    Provider Collaboration and Patient Care in the Use of
    Buprenorphine
  • Work-in-Recovery
  • Disparities in Health Services for Addiction-related
    Infections in Substance Abuse Treatment Programs
  • Hepatitis B and hepatitis C virus services offered by
    Substance Abuse Treatment Programs in the USA
  • Successful Implementation of an Office-Based Opiate
    Treatment Pilot Program Among a Marginalized
    Population- the San Francisco DPH OBOT Experience
  • Buprenorphine Detoxification for Opiate Withdrawal
    Increases Length of Inpatient Treatment
  • Integration of Medication-Assisted Treatment with
    Buprenorphine in an Intensive Outpatient Program
  • Pros and Cons of Prescribing Clonazepam in a
    Methadone Maintenance Clinic
  • Distance Traveled and Cross State Commuting Among
    OTP Patients
  • An Examination of the Impact of Mandatory THC
    Testing in MAT in Colorado
  • Use of Addnok (sublingual buprenorphine pills)in
    Maintenance Program in Dnepropetrovsk
  • Who is Getting Buprenorphine?
  • Adoption of Buprenorphine and Motivational
    Incentives in OTPs - Effects of Organizational
    Characteristics – Caseload - and Clinical Trial
    Exposure
  • Assisting Opiate Addicted Offenders Upon Re-entry-
    12 Month Outcomes for a Methadone Linkage
    Program
  • Use of Other Drugs that May Affect Heart Health
    Among Patients in Early Methadone Maintenance
    Treatment
  • Buprenorphine Treatment at a New York City
    Methadone Program- 3 Years Experience
  • Improving Methadone Treatment Retention through
    Motivational Interviewing
For questions or additional information regarding Booth Reservations and Sponsorship please contact: Wendy P. Stevens Trade Show Manager TALLEY MANAGEMENT GROUP, INC. at Phone: 856.423.7222 Ext. 262, Email: wstevens@talley.com

AATOD Conference Contacts
C/O Talley Management Group, Inc.

Cheryl Gallagher, Meeting Manager, aatod@talley.com
Wendy Stevens, Trade Show Manager, wstevens@talley.com
Sue Parker, Sales Associate, sparker@talley.com

19 Mantua Road
Mt. Royal, New Jersey 08061
Phone: 856-423-3091
Fax: 856-423-3420